4-叔丁基苯异硫氰酸酯 | 19241-24-8

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-叔丁基苯异硫氰酸酯
• 中文别名: 4-叔丁基苯基异硫氰酸酯；4-叔丁基苯基异氰酸酯
• 英文名称: 4-(tert-butylbenzyl)isothiocyanate
• 英文别名: 4-tert-butylphenyl isothiocyanate；1-(tert-butyl)-4-isothiocyanatobenzene；1-tert-butyl-4-isothiocyanatobenzene
• CAS: 19241-24-8
• 化学式: C₁₁H₁₃NS
• 分子量: 191.297
• InChiKey: OCGNNCBNRBTUCG-UHFFFAOYSA-N

物化性质

• 熔点：
  42 °C
• 沸点：
  92 °C
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  44.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  KEEP COLD, LACHRYMATOR, TOXIC
• 危险品标志：
  T
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  2811
• 海关编码：
  2930909090
• 安全说明：
  S26,S36/37/39
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P310+P330,P302+P352+P332+P313+P362+P364,P304+P340+P311,P305+P351+P338+P337+P313,P403+P233,P405,P501
• 危险性描述：
  H301+H331,H315,H319,H335
• 储存条件：
  请保持冷静。

SDS

Name:	4-(tert-Butyl)phenyl isothiocyanate Material Safety Data Sheet
Synonym:
CAS:	19241-24-8

Section 1 - Chemical Product MSDS Name:4-(tert-Butyl)phenyl isothiocyanate Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
19241-24-8	4-(tert-Butyl)phenyl isothiocyanate		unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye irritation. Lachrymator (substance which increases the flow of tears).
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 19241-24-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: colorless
Odor: pungent odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 92 - 94 deg C @0.5mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H13NS
Molecular Weight: 191.3

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Bases, oxidizing agents, reducing agents, amines, acids.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 19241-24-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(tert-Butyl)phenyl isothiocyanate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 19241-24-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 19241-24-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 19241-24-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-叔丁基苯异硫氰酸酯 在 ammonium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 (4-叔丁基苯基)硫脲
  参考文献：
  名称：

  Design, Synthesis, X-ray Crystallographic Analysis, and Biological Evaluation of Thiazole Derivatives as Potent and Selective Inhibitors of Human Dihydroorotate Dehydrogenase

  摘要：

  Human dihydroorotate dehydrogenase (HsDHODH) is a flavin-dependent mitochondrial enzyme that has been certified as a potential therapeutic target for the treatment of rheumatoid arthritis and other autoimmune diseases. On the basis of lead compound 4, which was previously identified as potential HsDHODH inhibitor, a novel series of thiazole derivatives were designed and synthesized. The X-ray complex structures of the promising analogues 12 and 33 confirmed that these inhibitors bind at the putative ubiquinone binding tunnel and guided us to explore more potent inhibitors, such as compounds 44, 46, and 47 which showed double digit nanomolar activities of 26, 18, and 29 nM, respectively. Moreover, 44 presented considerable anti-inflammation effect in vivo and significantly alleviated foot swelling in a dose-dependent manner, which disclosed that thiazole-scaffold analogues can be developed into the drug candidates for the treatment of rheumatoid arthritis by suppressing the bioactivity of HsDHODH.

  DOI：

  10.1021/jm501127s
• 作为产物：
  描述：

  (4-tert-butylphenyl)carbamodithioic acid 在 氯甲酸乙酯 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 1.0h， 以96 g的产率得到4-叔丁基苯异硫氰酸酯
  参考文献：
  名称：

  Iminodiaziridines 的合成和 15N NMR 谱 - 1-Aryl-3-iminodiaziridines 的环扩展为 1H-和 3aH-Benzimidazoles、2H-Indazoles 和 5H-Dibenzo[d,f][1,3]diazepines

  摘要：

  亚氨基二氮丙啶是通过 (i) 用 N-氯胍的叔丁醇钾进行 1,3-脱氯化氢合成的，由 N,N',N"-取代的胍与次氯酸叔丁酯原位生成，以及 (ii) 碱介导的 1 ,3-从 N,N',N"-取代的羟基胍 O-磺酸中消除硫酸。在升高的温度下，（烷基亚氨基）二氮丙啶通过 1,3-移位、[2+1] 环消去反应得到异氰化物和二氮烯，以及开环消除反应得到亚烷基胍。N'-芳基-N-羟基胍O-磺酸提供（N-芳基亚氨基）二氮丙啶，但不提供1-芳基-3-亚氨基二氮丙啶，而是提供重排的异构体。含有全氘化叔丁基的前体得到重排产物，显示完全混乱。这表明 1-芳基-3-亚氨基二氮丙啶是中间体，可进行非常快速的简并价异构化。如果邻芳基位置被取代，则可获得高产率的（芳基亚氨基）二氮丙啶以及 2-亚氨基-2,3-二氢-3aH-苯​​并咪唑。否则，2-氨基-1H-苯并咪唑和强荧光 3-氨基-2H-吲唑，源自难以捉摸的 1-

  DOI：

  10.1002/ejoc.200900350

文献信息

• Substituted benzimidazoles and methods of preparation
  申请人：Dimitroff Martin

  公开号：US20070049622A1

  公开（公告）日：2007-03-01

  Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R 1 , R 2 , R 3 , R 4 , a, b, and c are defined herein

  提供了制备新的取代苯并咪唑化合物的方法，其化学式为（I），用于治疗激酶介导的疾病，其中R1、R2、R3、R4、a、b和c在此定义。
• Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFV600E and VEGFR-2 dual inhibitors
  作者：Yuanyuan Wang、Shanhe Wan、Zhonghuang Li、Yu Fu、Guangfa Wang、Jiajie Zhang、Xiaoyun Wu

  DOI：10.1016/j.ejmech.2018.05.054

  日期：2018.7

  Aiming to explore novel BRAFV600E and VEGFR-2 dual inhibitors, a series of 1H-pyrazolo[3,4-d]pyrimidine derivatives were designed, synthesized and biologically evaluated in this study. Most of the synthesized 1H-pyrazolo[3,4-d]pyrimidine compounds displayed moderate to high potent activity in both enzymatic and cellular proliferation assays. Among these compounds, 9e, 9g, 9m and 9u showed remarkably

  为了探索新型的BRAF V600E和VEGFR-2双重抑制剂，在本研究中设计，合成了一系列1 H-吡唑并[3,4-d]嘧啶衍生物。在酶促和细胞增殖试验中，大多数合成的1 H-吡唑并[3,4-d]嘧啶化合物均显示中等至高强度的活性。在这些化合物中，与阳性对照索拉非尼相比，9e，9g，9m和9u表现出对BRAF V600E和VEGFR-2激酶的显着高抑制活性。特别地，化合物9u还显示出对BRAF的有效抗增殖活性表达V600E的A375（IC 50  = 1.74μM）和H-29（IC 50  = 6.92μM）以及表达VEGFR-2的HUVEC（IC 50  = 5.89μM），也可与索拉非尼媲美。此外，激酶选择性谱显示9u对野生型BRAF和15种其他测试的蛋白激酶几乎没有或没有明显的抑制活性。流式细胞仪分析表明，化合物9u主要在G 0 / G 1期阻滞了A375和HUVEC细胞系，并具有浓度
• Substituted benzazoles and methods of their use as inhibitors of Raf kinase
  申请人：——

  公开号：US20040122237A1

  公开（公告）日：2004-06-24

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。
• Synthesis, structure–activity relationship and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase
  作者：Fanxun Zeng、Tiantian Qi、Chunyan Li、Tingfang Li、Honglin Li、Shiliang Li、Lili Zhu、Xiaoyong Xu

  DOI：10.1039/c7md00081b

  日期：——

  series of 4-thiazolidinone derivatives were synthesized and evaluated as novel human dihydroorotate dehydrogenase (hDHODH) inhibitors. Compounds 26 and 31 displayed IC50 values of 1.75 and 1.12 μM, respectively. The structure–activity relationship was summarized. Further binding mode analysis revealed that compound 31 could form a hydrogen bond with Tyr38 and a water-mediated hydrogen bond with Ala55,

  合成了一系列的4-噻唑烷酮衍生物，并作为新型人二氢乳清酸脱氢酶（h DHODH）抑制剂进行了评估。化合物26和31的IC 50值分别为1.75和1.12μM。构效关系进行了总结。进一步的结合模式分析表明，化合物31可以与Tyr38形成氢键，并与Ala55形成水介导的氢键，这对于维持该系列化合物的生物活性可能是必需的。R上苯基对位或间位的进一步结构优化将导致鉴定更有效的hDHODH抑制剂。
• Na₂S₂O₈-mediated efficient synthesis of isothiocyanates from primary amines in water
  作者：Zhicheng Fu、Wenhao Yuan、Ning Chen、Zhanhui Yang、Jiaxi Xu

  DOI：10.1039/c8gc02261e

  日期：——

  We have developed two green, practical, and efficient procedures, including a one-pot one, to synthesize isothiocyanates from amines and carbon disulfide via desulfurization with sodium persulfate. Water is used as the solvent. Basic conditions are necessary for good chemoselectivity for isothiocyanates. Structurally diverse linear and branched alkyl amines and aryl amines are readily converted to isothiocyanates

  我们已经开发了两种绿色，实用且有效的方法，包括一锅法，可通过胺和二硫化碳通过胺合成异硫氰酸酯。用过硫酸钠脱硫。使用水作为溶剂。为了使异硫氰酸酯具有良好的化学选择性，必须具备碱性条件。通过两种方法，结构令人满意的直链和支链烷基胺和芳基胺很容易以令人满意的产率转化为异硫氰酸酯。卤素，苄基CH键，甲硫基，硝基，酯，烯基，富电子或不足的（杂）芳基，乙炔基，甚至酚和醇羟基均被很好地耐受。在水中一锅法也可用于从手性胺制备手性异硫氰酸酯，以及用游离氨基修饰生物活性结构。在大规模制备中，开发了独立于柱色谱法的简单实用的纯化方法。

表征谱图